• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Erlotinib (2)

Pharmacogenomic Information
  

Drug Link
in Drugs@FDA
Therapeutic AreaHUGO
Symbol
Referenced
Subgroup
Labeling Sections with
Pharmacogenomic
Information
ErlotinibOncologyEGFREGFR exon 19
deletion or
exon 21 substitution
(L858R) positive

Indications and Usage
Dosage and Administration
Clinical Pharmacology
Clinical Studies

 

back to Table of Pharmacogenomic Biomarkers in Drug Labeling